Abstract: The present disclosure relates to, inter alia, compositions and methods, including heterologous chimeric proteins that find use, inter alia, in the treatment of nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), obesity, or metabolic syndrome.

Abstract: The present disclosure relates to, inter alia, compositions and methods for nucleic acid-based delivery of chimeric proteins that find use in the treatment of a disease or disorder such as selected from cancer, autoimmunity, fibrotic disease, and other inflammatory disorders.

Abstract: The present disclosure relates to, inter alia, compositions and methods, including heterologous chimeric proteins that find use, inter alia, in the treatment of inflammatory conditions of the integumentary system.

Abstract: The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.

Abstract: The present disclosure relates, inter alia, to compositions and methods, including chimeric proteins, and nucleic acids encoding the chimeric proteins having a first domain comprising an extracellular domain of a first transmembrane protein, a first secreted protein, or a first membrane-anchored extracellular protein and a second domain comprising an extracellular domain of a second transmembrane protein, a second secreted protein, or a second membrane-anchored extracellular protein, in which either or both of the first domain and the second domain decreases self-directed immune system activity when bound to its ligand/receptor. Accordingly, the present disclosure find use in the treatment of autoimmune diseases, and particularly, inflammatory bowel diseases.

Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.

Abstract: The present disclosure relates, inter alia, to methods of treating cancer with chimeric proteins comprising an extracellular domain of human signal regulatory protein ? (CD172a (SIRP?)) and an extracellular domain of human CD40 ligand (CD40L), including doses and regimens.

Abstract: The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.

Abstract: The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.

Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.

Abstract: The present disclosure relates to, inter alia, compositions and pharmaceutical compositions, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.

Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins and combination therapies that find use in the treatment of disease, such as cancer and/or an inflammatory disease.

Abstract: The present disclosure relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer.

Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins and combination therapies that find use in the treatment of disease, such as cancer and/or an inflammatory disease.

Abstract: The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.

Abstract: The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.

Abstract: The present invention relates, inter alia, to compositions and methods, including TIGIT- and/or LIGHT-based chimeric proteins that find use in the treatment of disease, such as cancer and an inflammatory disease.

Abstract: The present disclosure relates, inter alia, to compositions and methods, including heterodimeric proteins, including a heterodimeric protein comprising BTN2A1/3A1-Fc- and an scFv that specifically binds to a cancer targeting domain, that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.

Abstract: The current disclosure relates to, inter alia, mutant derivatives of PD-1 protein. The current disclosure also relates to compositions and methods that find use in the treatment of diseases, such as immunotherapies for cancer and autoimmunity.

Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.